Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY101921 plus TROP2 ADC in advanced malignant solid tumors
CTR20262727Phase 2Active
- Sponsor
- Combi-Blocks
- Start
- Jul 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BY101921, Trop2 antibody-drug conjugate in Non-hematologic malignancy, sponsored by Combi-Blocks. Started Jul 2026; status: active.
02
Drugs
BY101921Trop2 antibody-drug conjugate
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20262727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262727.